Samsung Biologics’s No. 4 plant in Incheon / Courtesy of Samsung Biologics
Samsung Biologics, a biotech arm of Korea’s Samsung Group, stated Tuesday it has acquired a contract manufacturing deal price 2.07 trillion received ($1.4 billion) from a Europe-based biopharmaceutical agency.
Within the largest-ever contract manufacturing deal, Samsung Biologics will manufacture a biomedicine for the European firm from Dec. 13, 2024, by Dec. 31, 2030, the corporate stated in a regulatory submitting.
The corporate did not present the identify of the drugs or the contractor.
The newest deal represents 40 % of Samsung Biologics‘ general contracts received final 12 months, price 5.4 trillion received. (Yonhap)
